Lord Ravensdale

The department recognises the potential importance of americium for advanced technologies, including space power systems.

Whilst no decisions have been taken, government continue to explore opportunities for collaboration with industry. Any future private sector involvement would need to comply with strict safety, security and regulatory frameworks.

The Department is supporting the UK’s National Nuclear Laboratory (UKNNL)’s work to extract americium from the UK’s civil separated plutonium inventory at Sellafield for the European Space Agency’s (ESA’s) ENDURE Programme.

Discussions are taking place with industry, public bodies and wider government prior to any decision making beyond current commitments.

The nuclear industry has a proud record of supporting tens of thousands of well-paid, highly skilled, unionised jobs, which are vital to communities across the country.

The Nuclear Decommissioning Authority permanently employs 17,500 people and invests £45m each year in apprentice and graduate development supporting the Nuclear Skills Agenda. The Nuclear Decommissioning Authority also supports approximately 5,000 companies as part of its supply chain. The economic impact of the NDA group was reported upon in 2022 [1] and has most recently undertaken an economic impact assessment which will be published this financial year [2]

[1] Microsoft Word - Magnox economic impact assessment - 2022, The economic contribution of the NDA to the West Cumbria economy, Dounreay_Socio-economic_report_2022.pdf

[2] at Nuclear Decommissioning Authority - GOV.UK

The government is committed to ensuring energy efficiency schemes deliver measurable benefits for households. As part of the Warm Homes Plan, officials are exploring how to better target support and improve outcomes.

While the government has not made a formal assessment of the Sustainable Energy Association’s specific proposal, we will continue to engage with stakeholders on innovative approaches to improve affordability and effectiveness of retrofit delivery.

Decarbonising heating is one of the biggest challenges facing the UK getting to Net Zero by 2050. A range of technologies are likely to be required including heat pumps, heat networks and biomethane. As part of the Government's ambitious Warm Homes Plan, we will upgrade up to 5 million homes across the country by accelerating the installation of efficient new technologies like heat pumps, solar, home batteries and insulation. We will publish more details soon.

Following the Chancellor's commitment to progress Midlands Rail Hub in the 2025 Spending Review the procurement of the alliance that will design and deliver Midlands Rail Hub is currently ongoing.

We are working with Network Rail, Midlands Connect, and West Midlands Rail Executive, to maximise the benefits of Midlands Rail Hub throughout the region. Midlands Connect are leading the development of the rationale for the scheme, including the distribution of socio-economic benefits, and will be able to provide more detail.

Medical radioisotopes can be produced in different ways, and the United Kingdom has a comprehensive network of cyclotrons used for radioisotope manufacture. These tend to be placed close to the point of use due to the short half-life of these products. The radioisotopes manufactured in these cyclotrons are not suitable for all uses, and so hospitals and trusts in England use a significant number of isotopes manufactured in research reactors. There are currently no reactors in the UK that manufacture medical isotopes, all of these are therefore imported.

The Government does not have any current plans to produce a strategy or to consult on the potential for further domestic medical radioisotope manufacture. However, the Government prioritises the reliable supply of medicines, including the supply of medical radioisotopes for critical services. The Government therefore offers support for private investors and developers to increase manufacture capacity.

The Government has made up to £520 million available through the Life Sciences Innovative Manufacturing Fund to support UK manufacture of medicine and medical technology products. Applications looking to establish, expand, or improve the UK-based manufacture of medical radioisotopes for diagnostic or therapeutic applications can apply to this fund.

The Government also recently announced a £54 million funding package for eight innovative research and development projects, including £9.9 million earmarked for Project Alpha 10.6 to explore how to make medical treatments from legacy nuclear material, something that could unlock the UK’s potential to develop promising new cancer therapies.

Medical radioisotopes can be produced in different ways, and the United Kingdom has a comprehensive network of cyclotrons used for radioisotope manufacture. These tend to be placed close to the point of use due to the short half-life of these products. The radioisotopes manufactured in these cyclotrons are not suitable for all uses, and so hospitals and trusts in England use a significant number of isotopes manufactured in research reactors. There are currently no reactors in the UK that manufacture medical isotopes, all of these are therefore imported.

The Government does not have any current plans to produce a strategy or to consult on the potential for further domestic medical radioisotope manufacture. However, the Government prioritises the reliable supply of medicines, including the supply of medical radioisotopes for critical services. The Government therefore offers support for private investors and developers to increase manufacture capacity.

The Government has made up to £520 million available through the Life Sciences Innovative Manufacturing Fund to support UK manufacture of medicine and medical technology products. Applications looking to establish, expand, or improve the UK-based manufacture of medical radioisotopes for diagnostic or therapeutic applications can apply to this fund.

The Government also recently announced a £54 million funding package for eight innovative research and development projects, including £9.9 million earmarked for Project Alpha 10.6 to explore how to make medical treatments from legacy nuclear material, something that could unlock the UK’s potential to develop promising new cancer therapies.

The Department has not made a specific assessment of the Welsh Government’s project to build a reactor for medical radioisotope manufacture.

The Department regularly engages with suppliers, specialist clinicians, the British Nuclear Medicine Society, and the UK Radiopharmacy Group to support the continued supply of medical radioisotopes for National Health Services.

My department has been conducting research into the practical, technical and economic impacts of regulating embodied carbon in new buildings. This research is now nearing completion and will inform future policy decisions, including when and how to seek views on the measurement and reduction of embodied carbon.

The Future Homes and Buildings Standards consultation was published in December 2023 and closed in March 2024, and a government response has not yet been issued. The consultation proposed that the new standards would apply to all new domestic and non-domestic buildings.

We fully support the need for low carbon homes and buildings, fit for a net zero future. We are reviewing proposals and feedback from the Future Homes and Buildings Standards consultation and will publish the government response in due course.